Clinical trials: Mammographic Density
Breast Cancer
Green Tea and Reduction of Breast Cancer Risk
RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of breast cancer. PURPOSE: This phase II trial is studying how well green tea extract works in preventing breast cancer compared to a placebo…
- Trial name
- NCT00917735
- Testing
- Green tea extract supplement
- Where
- 5 sites in United States
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Mammographic Density, Abnormal Mammogram
KEEPS Mammographic Density And Breast Health Ancillary Study
Combined estrogen and progestin therapy has been shown to increase mammographic density and incidence of breast cancer in randomized trials.
- Trial name
- KEEPS MDBHAS (NCT02524561)
- Testing
- CEE pill, Estradiol patch, Active Progesterone
- Where
- United States
- Volunteers
- 517 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Mammographic Breast Density
Topical Endoxifen in Women
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change.
- Trial name
- CREME (NCT04616430)
- Testing
- Topical endoxifen
- Where
- Sweden
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Breast Cancer, Mammographic Density
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures.
- Trial name
- Karisma-1 (NCT04079517)
- Testing
- Tamoxifen
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Risk Reduction, Mammographic Density Reduction
Low Dose Tamoxifen for Mammographic Density Reduction
KARISMA2 is a randomized, double-blinded, six-armed placebo controlled study to identify a low dose of tamoxifen, with less side-effects and a density reduction non-inferior to the standard dose of 20 mg.
- Trial name
- KARISMA2 (NCT03346200)
- Testing
- Tamoxifen Oral Tablet
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Per Hall
Breast Cancer
Soy Isoflavones and Breast Cancer Risk Reduction
Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear.
- Trial name
- NCT00204490
- Testing
- isoflavones, carbohydrate
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston